The Center for Rheumatic Disease, Allergy, & Immunology

Quick facts

Phase 2 pipeline

• IV Gamunex 10% · Immunology
  Immunomodulation through the administration of intravenous immunoglobulin

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• The Center for Rheumatic Disease, Allergy, & Immunology portfolio CI brief
• The Center for Rheumatic Disease, Allergy, & Immunology pipeline updates RSS

Related

• Sector hub: All tracked pharma companies